Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors

PURPOSE: This phase Ib trial was designed to evaluate the safety and early efficacy signal of the combination of imatinib and binimetinib in patients with imatinib-resistant advanced gastrointestinal stromal tumors (GISTs). PATIENTS AND METHODS: This trial used a standard 3 + 3 design to determine t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Ping, Qin, Li-Xuan, Camacho, Niedzica, Kelly, Ciara M., D'Angelo, Sandra P., Dickson, Mark A., Gounder, Mrinal M., Keohan, Mary L., Movva, Sujana, Nacev, Benjamin A., Rosenbaum, Evan, Thornton, Katherine A., Crago, Aimee M., Francis, Jasmine H., Martindale, Moriah, Phelan, Haley T., Biniakewitz, Matthew D., Lee, Cindy J., Singer, Samuel, Hwang, Sinchun, Berger, Michael F., Chen, Yu, Antonescu, Cristina R., Tap, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012681/
https://www.ncbi.nlm.nih.gov/pubmed/35110417
http://dx.doi.org/10.1158/1078-0432.CCR-21-3909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012681/
https://www.ncbi.nlm.nih.gov/pubmed/35110417
http://dx.doi.org/10.1158/1078-0432.CCR-21-3909

Ejemplares similares